Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. 1994

G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
Laboratoire de Chimie Bioorganique, URA Centre National de la Recherche Scientifique 488, Université de Montpellier II, Sciences et Techniques du Languedoc, France.

The L enantiomer of 2',3'-dideoxycytidine (DDC) was recently shown to inhibit selectively human immunodeficiency virus type 1 (HIV-1) in vitro. In the current study, the potent anti-HIV activity of L-DDC was confirmed and extended to several HIV-1 and HIV-2 strains in various cell culture systems, including primary human lymphocytes and macrophages. Furthermore, its 5-fluoro congener, beta-L-2',3'-dideoxy-5-fluorocytidine (L-FDDC), was found to have more potent anti-HIV activity and a higher therapeutic index in acutely infected human peripheral blood mononuclear cells. These compounds had no marked activity against HIV-1 isolates resistant to the oxathiolane pyrimidine nucleosides (-)-beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine [(-)-FTC] and (-)-beta-L-2',3'-dideoxy-3'-thiacytidine, but 3'-azido-3'-deoxythymidine (AZT)-resistant viruses were susceptible to L-DDC and L-FDDC. Cytotoxicity studies with human myeloid progenitor cells indicated that L-DDC and L-FDDC had median inhibitory concentrations comparable to those of AZT, DDC, and FDDC, but L-DDC and L-FDDC were significantly less toxic than AZT, DDC, and FDDC when erythroid progenitor cells were used. L-FDDC had the highest selectivity indices (6,000 and 9,000 for erythroid and myeloid progenitor cells, respectively) of all the compounds evaluated. Further preclinical development of L-FDDC is warranted in order to determine its potential usefulness in the treatment of HIV infections.

UI MeSH Term Description Entries
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170

Related Publications

G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
May 1992, Journal of medicinal chemistry,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
January 1995, Journal of medicinal chemistry,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
November 1994, Molecular pharmacology,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
July 1998, Antimicrobial agents and chemotherapy,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
February 2005, Antimicrobial agents and chemotherapy,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
September 1993, Molecular pharmacology,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
May 1998, Molecular pharmacology,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
May 1989, Molecular pharmacology,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
January 1994, Biochemical pharmacology,
G Gosselin, and R F Schinazi, and J P Sommadossi, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and J L Imbach
January 1987, The Journal of biological chemistry,
Copied contents to your clipboard!